

RETRO-ACTIVE NEWS

Newsletter of the Center for Retrovirus Research & Comprehensive Cancer Center, RNA Oncogenic Virus Program, The Ohio State University. Volume No.16, Fall Quarter, 2000.

ADMINISTRATIVE NEWS

The quarterly meeting of the RNA Tumor Virus Program/Center for Retrovirus Research Group was held November 6, 2000. Members were updated on the website: www.vet.ohio-state.edu/docs/retrovirus/index.html. Dr. Bruce Bunnell (Childrens Hospital) headed a committee to seek nominations for 2nd Annual Center for Retrovirus Research's "Distinguished Research Career Award" to be presented in April, 2001. This award recognizes a retrovirologist whose research is of particular significance and originality, and exhibits unique promise for seminal contributions in the future. Development of a Program of Projects in the area of HTLV/BLV was discussed and meetings planned to organize the proposal. Dr. Michael Para, who will coordinate the project with Dr. Larry Mathes, proposed an AIDS Center application to NIH.

SELECTED FACULTY APPOINTMENTS AND AWARDS

Dr. Lou Mansky (Molecular Virology, Immunology, & Medical Genetics) was appointed to a National Institutes of Health Study Section: ZRG1 VACC- Vaccines and Infectious Diseases.

Dr. Michael Podell (Veterinary Clinical Sciences) was awarded a grant entitled: "A feline model of neuroAIDS and drug abuse" from the National Institute on Drug Abuse, NIH (RO1) RFA-00-005. \$1,681,907 (Total costs), 9/30/00-9/29/05.

UPCOMING MEETINGS/SEMINARS OF INTERESTS

10th International Conference on Human Retrovirology: HTLV and Related Viruses, June 25-29, 2001, Dublin, Ireland. For more information meeting website: www.htlvconference.com

Retroviruses, Cold Spring Harbor, May 22-27th, 2001, Cold Spring Harbor NY. Abstracts due February 28, 2001. For more information website: www.cshl.org/meetings

8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL. Late Breaking Abstracts due January 3, 2001. For more information meeting website: www.retroconference.org

The Development of Antiviral Therapies, Symposium on HIV/AIDS, March 8-11, 2001. Palm Springs, Ca. Abstracts due February 1, 2001. For more information e-mail Nrdrisco@uci.edu.

GRADUATE STUDENT/POST-DOCTORAL FELLOWSHIP NEWS

From Dr. Bunnell's laboratory: Hajime Hiraragi, D.V.M. was the recipient of the *General Mason Fellowship* given by Children's Research Institute. The award is competitive and will pay a significant portion of his stipend through Year 4 of Graduate School. Also, Garret Newbound, D.V.M., Ph.D. has accepted a position at Eli Lilly (Elanco Division) in Indianapolis, IN as a Clinical Research Scientist.

<u>Veterinary Bioscience, MCDB, and OSBP graduate students</u> who presented platform or posters: Karen Duda's (Brooks lab) presented at the Annual OSBP Fall Research Symposium and at the Annual Meeting of Protein Society, San Diego in August. Student presentations at the Rustbelt RNA Meeting, Deer Creek State Park, Mt. Sterling, Ohio, in November included: Melinda Butsch (Boris-Lawrie lab), Murli Narayan & Jianxin Ye (Green lab). Wei Ding (Lairmore lab) presented a poster at the American Society of Virology Annual Meeting, Fort Collins, CO in July. Wayne Buck (Podell lab) in October presented a poster at the Society of Neurosciences Meeting in New Orleans, LA.

SELECTED RECENT PUBLICATIONS

Newbound, G.C., Cooper, J., O'Rourke J.P., Baskin C., and **Bunnell, B.A**. (2000) Analysis of safety and gene transfer efficiency of retrovirus producer cell transplantation and readministration for in situ gene transfer to rhesus macaque hematopoietic cells. <u>Exp.Hematol.</u> (in press).

Mansky, L.M., and K.S. Cunningham. Virus mutators and antimutators: roles in evolution, pathogenesis and emergence. <u>Trends in Genetics</u> 16: 512-517, 2000.

Mansky, **L.M**., and L.C. Bernard. 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of HIV-1. J. Virol. 74:9532-9539.

Mansky, L.M. 2000. In vivo analysis of HTLV-1 reverse transcription accuracy. <u>J. Virol.</u> 74:9525-9531, 2000.

Mansky, **L.M**., Preveral, S., Selig, L., Benarous, R., and S. Benichou. The interaction of Vpr with uracil DNA glycosylase modulates the HIV-1 in vivo mutation rate. <u>J.Virol.</u> 74:7039-7047, 2000.

Sarter M and **Podell M.** Preclinical psychopharmacology of AIDS-Associated Dementia: lessons to be learned from the cognitive psychopharmacology of other dementias. <u>J Psychopharmacology</u> 14(3): 3-10, 2000.

Podell M, March P, Buck W, and **Mathes, LE**. The feline model of neuroAIDS: Understanding the progression to AIDS dementia. <u>J Psychopharmacology</u> 14(3):11-19, 2000.

Phipps AJ, Hayes KA, Buck WR, **Podell M**, **Mathes LE**. Disease progression following FIV molecular clone FIV-PPR DNA inoculation. J AIDS and Human Retrovirology 23:1-16, 2000.

Para, MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black J, et al. Reduced toxicity with the gradual Initiation of Trimethoprim-Sulfamethoxazole as Prophylaxis for Pneumocystis carinii Pneumonia. <u>J AIDS</u> 24:337-343, 2000.

Para MF, Glidden DV, Coombs RW, Collier AC, Condra JH, Craig C, Bassett R, Leavitt, Synder S, McAuliffe V, Boucher C. et al. Baseline HIV-1 phenotype, genotype and RNA response after switching from long term Saquinavir to Indinavir or Saquinavir soft gelatin capsule in ACTG 333. J Infect Dis. 182:733-743, 2000.

Wang T-G, Ye J, Lairmore MD, Green PL: In vitro cellular tropism of HTLV-2. <u>AIDS Research and Human</u> Retroviruses 16:1661-1668, 2000.

Albrecht B, Collins ND, Burniston MT, Nisbet, JW, Ratner L, **Green PL, Lairmore MD**: HTLV-1 ORF I p12^I is required for efficient viral infectivity in primary lymphocytes. <u>J. Virol.</u> 74:9828-9835, 2000.

Zhang W, Nisbet J, Bartoe J, Ding W, and **Lairmore M**. HTLV-1 p30^{II} functions as a transcription factor and differentially modulates CREB responsive promoters. <u>J. Virol.</u> 74: 11270-11277, 2000.

Butsch, M. and **Boris-Lawrie, K**. Translation is not required to generate virion precursor RNA in HIV-1-infected T cells. <u>J. Virol.</u> 74:11531-11537, 2000.

Hayes, KA, Phipps, AJ, Francke, S and **Mathes, LE**. Antiviral therapy reduces viral burden by does not prevent thyme involution in young cats infected with FIV. <u>Antimicrob. Agents Chemother</u>. 44:2399-2405, 2000.

Phipps, AJ, Hayes, KA, Al-dubaib, M, Roy-burman, P and **Mathes, LE**. Inhibition of FeLV subgroup A infection by coinoculation with subgroup B. <u>Virology</u> 277:40-47, 2000.

NEWSLETTER INPUT: Address comments to Dr. Michael Lairmore at lairmore.1@osu.edu. Additional information about retrovirus research at The Ohio State University can be found at the *Center for Retrovirus Research website: www.vet.ohio-state.edu/docs/retrovirus/index.html*